Sirona Biochem Corp (SBM) - Total Assets
Based on the latest financial reports, Sirona Biochem Corp (SBM) holds total assets worth CA$809.18K CAD (≈ $585.35K USD) as of July 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sirona Biochem Corp - Total Assets Trend (2011–2023)
This chart illustrates how Sirona Biochem Corp's total assets have evolved over time, based on quarterly financial data. Also see SBM company net worth for the company's overall valuation and market capitalisation.
Sirona Biochem Corp - Asset Composition Analysis
Current Asset Composition (October 2023)
Sirona Biochem Corp's total assets of CA$809.18K consist of 99.1% current assets and 0.9% non-current assets. Review SBM current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 55.4% |
| Accounts Receivable | CA$6.61K | 0.6% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2011–2023)
This chart illustrates how Sirona Biochem Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SBM stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sirona Biochem Corp's current assets represent 99.1% of total assets in 2023, an increase from 37.9% in 2011.
- Cash Position: Cash and equivalents constituted 55.4% of total assets in 2023, up from 6.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 59.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Sirona Biochem Corp Competitors by Total Assets
Key competitors of Sirona Biochem Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Sirona Biochem Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 1.50 | 4.63 |
| Quick Ratio | 0.34 | 1.50 | 4.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-1.57 Million | CA$361.97K | CA$3.34 Million |
Sirona Biochem Corp - Advanced Valuation Insights
This section examines the relationship between Sirona Biochem Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.64 |
| Latest Market Cap to Assets Ratio | 10.89 |
| Asset Growth Rate (YoY) | -20.0% |
| Total Assets | CA$1.03 Million |
| Market Capitalization | $11.23 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Sirona Biochem Corp's assets at a significant premium (10.89x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Sirona Biochem Corp's assets decreased by 20.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sirona Biochem Corp (2011–2023)
The table below shows the annual total assets of Sirona Biochem Corp from 2011 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-10-31 | CA$1.03 Million ≈ $746.59K |
-20.04% |
| 2022-10-31 | CA$1.29 Million ≈ $933.68K |
+0.25% |
| 2021-10-31 | CA$1.29 Million ≈ $931.33K |
-39.76% |
| 2020-10-31 | CA$2.14 Million ≈ $1.55 Million |
-49.79% |
| 2019-10-31 | CA$4.26 Million ≈ $3.08 Million |
+452.48% |
| 2018-10-31 | CA$770.51K ≈ $557.38K |
-38.41% |
| 2017-10-31 | CA$1.25 Million ≈ $904.98K |
-59.97% |
| 2016-10-31 | CA$3.13 Million ≈ $2.26 Million |
-24.65% |
| 2015-10-31 | CA$4.15 Million ≈ $3.00 Million |
+20.99% |
| 2014-10-31 | CA$3.43 Million ≈ $2.48 Million |
+2.51% |
| 2013-10-31 | CA$3.34 Million ≈ $2.42 Million |
+24.88% |
| 2012-10-31 | CA$2.68 Million ≈ $1.94 Million |
-22.51% |
| 2011-10-31 | CA$3.46 Million ≈ $2.50 Million |
-- |
About Sirona Biochem Corp
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, engages in the development and sale of cosmetic and pharmaceutical active ingredients in Canada and France. The company's programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, anti-wrinkle compound, and anti-viral program. The company … Read more